Details of the Drug

General Information of Drug (ID: DMFTAWU)

Drug Name
mRNA-2416
Synonyms mRNA-OX40L
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Ovarian cancer 2C73 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
mRNA therapy
Cross-matching ID
TTD ID
D70SHJ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TAX transcriptionally-activated glycoprotein 1 (OX40) TTBW580 TNFL4_HUMAN Replacement [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Lymphoma
ICD Disease Classification 2A80-2A86
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
TAX transcriptionally-activated glycoprotein 1 (OX40) DTT TNFSF4 9.04E-01 -0.12 -0.21
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT03323398) Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Moderna Therapeutics.
4 Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68.
5 Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105.
6 Clinical pipeline report, company report or official report of Moderna Therapeutics.
7 J Clin Oncol 33, 2015 (suppl; abstr 3056).